He et al. discovered that gastric cancer cells can inhibit CD8 T-cell metabolism via CD155/TIGIT signaling, thus suppressing the effector function of CD8 T cells and resulting in hyporesponsive antitumor immunity [16]. This evidence concerns the gene PVR and gastric cancer.